1995
In 1995 Amylin partnered with Johnson & Johnson's LifeScan subsidiary, which would share half of development costs and pay all pre-launch marketing costs for pramlintide.
“In that same year, they announced a new partnership with J &J, specifically their subsidiary LifeScan. Under those terms, J &J would share half of the development costs and pay all of the pre-launch marketing costs.”
Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:31:02
1998
In February 1998 Johnson & Johnson ended its partnership with Amylin after pramlintide trial results were weaker in type 2 diabetes than in type 1.
“Since type 2 diabetes is where the real money is at, J &J decides the juice isn't worth the squeeze.”
Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:32:56
2016
Rowena Yeo left Cargill in 2016 and joined Johnson & Johnson, first in its pharmaceutical sector.
“So I left Cargill in 2016 to join J &J in the pharmaceutical sector first.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:02:50
2019
Rowena Yeo became Johnson & Johnson's global chief technology officer in 2019.
“And then in 2019, I assumed my role of the global CTO for J &J and lead right now the technology services organization.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:02:50
2020
Alex Gorsky says Johnson & Johnson's earliest COVID-19 interest centered on its antiviral drugs before turning to a vector-based vaccine.
“And the early interest within Janssen and Johnson & Johnson was more around our antiviral portfolio.”
Alex Gorsky · Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky, 0:08:54
2020
Alex Gorsky says Pfizer and Moderna use an mRNA approach while Johnson & Johnson uses a vector approach.
“We know Pfizer and Moderna has taken an mRNA approach, we're utilizing a vector approach.”
Alex Gorsky · Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky, 0:20:40
2020
Alex Gorsky says research heads at Johnson & Johnson and Pfizer joined regular joint calls with US health leaders during the pandemic.
“Paul Stoffels, our head of research and development, is talking to Mikhail Dolstein, who's heading R &D for Pfizer, where they're on a joint phone call on Saturday morning”
Alex Gorsky · Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky, 0:12:47
2021
Alex Gorsky said Johnson & Johnson expected to provide hundreds of millions of vaccine doses in the first half of 2021 if its trials succeeded.
“now we're in a position where we feel confident that in the first half of 2021, we should be able to provide hundreds of millions of doses.”
Alex Gorsky · Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky, 0:16:01
2021
Johnson & Johnson released a long press release combining data from several studies, including a second shot given two months later.
“Johnson & Johnson putting like four studies worth of information into one very long press release where they talked about their second shot two months later.”
Meg Terrell · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:05:45
2022
Joaquin Duato became CEO of Johnson & Johnson in early 2022 after joining the company about 34 years earlier through Janssen Pharmaceuticals in Spain.
“Joaquin became CEO of J &J in early 2022, but he joined the company 34 years ago as part of Janssen Pharmaceuticals in his native Spain.”
Michal Lev-Ram · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:02:36
2023
John Reed, who had spent about five years running research and development at Sanofi, left the company and was hired by Johnson & Johnson as its chief scientific officer.
“John Reed, who had spent about five years running the research and development operation at Sanofi, would be leaving the company.”
Damian Garde · 246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid, 0:10:40
2023
John Reed replaces Mathai Mammen at Johnson & Johnson; Mammen was briefly a candidate for the Biogen CEO position before leaving J&J's top research role.
“he's replacing Matai Mamon, who we've spoken about, was briefly a candidate for the Biogen CEO position”
Damian Garde · 246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid, 0:10:40
2023
Johnson & Johnson is one of 49 companies on every Fortune 500 list since 1955 and ranked number 40 in the 2023 list.
“Johnson & Johnson has been one of 49 companies to be in the Fortune 500 list every single year since we've made it since 1955. This year they clocked in at number 40.”
Michal Lev-Ram · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:04:10
2023
Johnson & Johnson spun out its consumer health business as Kenvue earlier in 2023, and Kenvue is now publicly traded.
“Kenview, which is the company that you spun out just earlier this year. It's now publicly traded.”
Michal Lev-Ram · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:07:03
2023
Johnson & Johnson's credo, a statement of company principles, was written 80 years before 2023, according to Joaquin Duato.
“this year is the 80th anniversary of the credo that was written”
Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:12:10
Undated
Alex Gorsky says Johnson & Johnson's vaccine manufacturing builds on a technology called PER.C6, developed more than a decade earlier.
“And more than a decade ago, there was a technology called Percy6 that utilized a different kind of protein and biology in the production of vaccines.”
Alex Gorsky · Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky, 0:15:32
Undated
Alex Gorsky says earlier experience with SARS and Zika did not progress as far as the COVID-19 vaccine effort.
“We had had experiences with SARS and Zika that didn't go in near the direction that we've seen here.”
Alex Gorsky · Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky, 0:08:54
Undated
Seth Klarman bought his first stock, a share of Johnson & Johnson, at about age 10 using birthday money, and it split three for one soon afterward.
“I bought a share of Johnson & Johnson when I was around 10 years old with money I got from my birthday.”
Seth Klarman · Seth Klarman – Timeless Value Investing (EP.328), 0:08:23
Undated
Johnson & Johnson's technology services organisation covers infrastructure plus applications and platforms, including ERP, commercial applications and data platforms.
“And the second area encompasses applications and platforms, including supporting all the ERP platforms, commercial applications, and data platforms.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:04:02
Undated
Johnson & Johnson applies AI, machine learning, intelligent automation, data science, analytics and cloud computing to improve processes and efficiency, including accelerating drug discovery in R&D.
“leveraging technologies such as AI, machine learning, intelligent automation, data science, analytics, cloud computing, et cetera, to improve processes, to simplify workflow, to improve efficiencies.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:05:28
Undated
Johnson & Johnson has worked to raise digital skills among employees across the company, not only in IT.
“to raise the digital acumen within our employees across the organization, not just IT employees.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:06:03
Undated
Johnson & Johnson set up product teams with joint business and IT ownership.
“So specifically, we established what we call product teams with business and IT ownership.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:08:16
Undated
Johnson & Johnson's product teams use OKRs covering delivery velocity, backlog management, operational metrics and team health.
“we've also established OKRs objectives and key results that includes velocity how do we manage our backlog how do we look at operational metrics and team health”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:08:43
Undated
Johnson & Johnson adopted a hybrid cloud approach because of its size and scale.
“we knew that we needed the flexibility of a hybrid cloud approach.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:10:29
Undated
J&J's hybrid cloud combines public cloud offerings with a virtualized private cloud in its own data centre.
“leveraging the offerings of public cloud with our virtualized private cloud environment within our data center.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:10:59
Undated
J&J's data and compute demands for drug discovery include imaging and genomics data.
“And we can see these data requirements ranges from imaging data, genomics data, so you can imagine the demand on our environment.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:11:31
Undated
J&J retrained staff from managing on-premises data centres to cloud engineering, cloud operations and FinOps.
“to retrain and expand the skill set of our team from managing on-prem data centers to cloud engineering, understanding cloud operations, and FinOps right in the cloud space.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:12:06
Undated
J&J worked with several cloud providers to enable knowledge transfer and hands-on upskilling.
“retraining also include working with our several cloud providers to make sure that we are enabling the knowledge transfer”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:12:06
Undated
J&J uses steering committees to align business and IT strategies with clear accountability on both sides.
“to establish steering committee so that we can align business strategies and goals and with clear accountability on both business and IT teams”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:14:05
Undated
J&J has established a Global Data Science Council and Global Intelligent Automation Councils with business and IT representation.
“we have established councils such as Global Data Science Council, Global Intelligent Automation Councils.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:16:01
Undated
Rowena Yeo represents IT on J&J's Global Data Science Council.
“So I represent IT in the Global Data Science Council, for example”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:16:40
Undated
Yeo describes Johnson & Johnson's purpose as blending art, science and ingenuity to profoundly change the trajectory of health for humanity.
“it's about unleashing the JMJ purpose, which is to blend art, science and ingenuity to profoundly change the trajectory of health for humanity.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:17:26
Undated
J&J uses AI to automate tasks such as patch management and to build chatbots for employees and customers.
“automating task, be it within technology itself, patch management, or developing chatbots to support our employees and customers.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:18:34
Undated
Johnson & Johnson has used AI to speed up drug discovery.
“We have also used AI to speed up drug discovery.”
Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:19:09
Undated
Johnson & Johnson applies criteria to volunteers for its citizen development program, such as data experience and technical aptitude.
“J and J has a s a series of criteria that they apply to you once you volunteer.”
Tom Davenport · Leading a Workforce Empowered by New AI Tools, 0:23:03
Undated
Johnson & Johnson faced a settlement of about $9 billion over a class action lawsuit alleging its baby powder caused cancer.
“we all know about this settlement, $9 billion class action lawsuit alleging that J &J's baby powder had caused cancer”
Michal Lev-Ram · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:02:36
Undated
Joaquin Duato said Johnson & Johnson has had only eight CEOs in about 130 years and that he is the first born outside the United States.
“In our 130 years of history, we have had only eight CEOs. And I am the first one who is not born in the U.S.”
Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:04:39
Undated
Joaquin Duato was not advanced to a second interview when he first interviewed with Johnson & Johnson after graduate school, and he joined another pharmaceutical company before returning.
“when I finished graduate school, I interviewed with Johnson & Johnson, and I didn't make it to the second interview.”
Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:05:33
Undated
Joaquin Duato said average employee tenure at Johnson & Johnson in the U.S. is more than a decade.
“Our average tenure, for example, in the U.S. is more than a decade.”
Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:06:41
Undated
Joaquin Duato said competing with L'Oreal in skincare while also competing in biologics and surgical robotics was too complex for Johnson & Johnson.
“For us, it was very complex to be able to compete with L 'Oreal, as you mentioned, in skincare and at the same time competing biologics with biopharmaceutical companies and in surgical robotics with medical technology companies.”
Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:07:34
Undated
Joaquin Duato said Johnson & Johnson can work in cell therapy, robotic surgery, genetic and mRNA therapeutics and smart implants.
“We can do cell therapy, but we can do robotic surgery. We can do genetic or mRNA therapeutics, and we can do also smart implants.”
Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:11:26
Undated
Johnson & Johnson initially took a let-a-thousand-flowers-bloom approach to generative AI.
“they had a very conscious sort of let a thousand flowers bloom approach to generative AI in the initial years.”
Andrew Palmer · A Need for Nuance: The Economist’s Andrew Palmer, 0:13:14
Undated
At Johnson & Johnson, about 15% of generative AI projects delivered 85% of the value, according to Andrew Palmer.
“there's only 15% of projects were delivering 85% of the value”
Andrew Palmer · A Need for Nuance: The Economist’s Andrew Palmer, 0:13:39
Undated
Johnson & Johnson moved to a centralized, priority-driven AI approach with a central AI council and a data council.
“they have now pivoted to a much more kind of priority-driven, centralized approach, where, you know, there's a central AI Council”
Andrew Palmer · A Need for Nuance: The Economist’s Andrew Palmer, 0:14:19
Undated
Seth Klarman says he bought his first stock, a share of Johnson & Johnson, at around age 10.
“I bought my first stock with some bar mitzvah money when I was around 10 years old.”
Seth Klarman · Value Investing Legend and Warren Buffett Disciple Seth Klarman, 0:04:53